In short. The areas that carry the highest risk of vascular occlusion after an injectable filler are the glabella, nose, forehead, temple and tear trough. What sets them apart is not how difficult they are to inject but how their arteries connect with the blood supply of the eye. That pattern is predictable in outline and variable between people.
Key points
- Risk follows the arteries that connect with the eye, not the difficulty of the injection.
- The glabella sits at the top of most lists because its arteries lead to the eye.
- The nose, forehead, temple and tear trough share dense or readily entered vessels.
- A blunt cannula lowers the chance of entering a vessel; it does not remove it.
- Risk in these areas is managed with technique, product and a plan for failure.
Why do these areas carry more risk?
Vascular occlusion can follow an injection almost anywhere on the face, and it is reported most often in a small number of areas: the glabella, the nose, the forehead, the temple and the tear trough. That pattern is not about those areas being delicate. It is about the arteries that run through them and the fact that several share a blood supply with the retina. Knowing which areas are different explains why the same product and volume can carry different consequences depending on where it is placed.
Two features do most of the work. The first is the presence of arteries that communicate with the ophthalmic circulation, so that material entering one of them can travel towards the eye as well as towards the skin. The second is the direction of flow through the small vessels in these areas, which allows material injected under pressure to travel backwards along a vessel before being carried forward into territory far from the needle. Where the two coincide and the skin is thin, a small volume can reach territory no one intended to treat.
The anatomy is predictable, and it is not identical
Facial arteries follow recognisable patterns, and the variations between people are considerable. That is why a careful approach can be uneventful in one patient and not in another, and why the same area is treated differently from one face to the next. It is also why the findings are worth knowing regardless of who is injecting.
Which areas are named most often?
| Area | Arteries and connections | What makes it notable | Risk |
|---|---|---|---|
| Glabella | Arteries that connect directly with the circulation of the eye | A direct route towards the ophthalmic circulation | Top of most lists |
| Nose | A dense blood supply with connections to the forehead and the eye | Many vessels and several routes | Named among the highest-risk areas |
| Forehead | Vessels running in a plane where they are readily entered | Easy for a needle tip to enter | Named among the highest-risk areas |
| Temple | Named arteries large enough to accept a needle tip | Large vessel calibre | Named among the highest-risk areas |
| Tear trough | Vessels supplying both the skin and the eye, in thin skin | Thin skin close to the eye's supply | Named among the highest-risk areas |
The glabella carries arteries that connect directly with the circulation of the eye, which is why it sits at the top of most lists. The other four are named for a different reason in each case: vessel density and reach in the nose, an easily entered plane in the forehead, vessel calibre in the temple, and thin skin over vessels shared with the eye in the tear trough.
Risk is managed, not eliminated
In practice, an injector may prefer a blunt cannula, use a smaller volume at each pass, place the product in a plane away from the named vessels, and stop rather than persist if the patient reports disproportionate pain. Some will decline to treat an area altogether, or suggest an operation instead. What none of these measures does is remove the possibility, and no patient should be told that it does.
Why a blunt cannula does not remove the risk
A blunt cannula is generally regarded as less likely to enter a vessel than a sharp needle, and it is often preferred in these areas for that reason. It does not remove the risk, because a cannula can still enter a vessel that it meets end-on, and because the anatomy varies between people. Neither instrument makes an occlusion impossible. The same reasoning applies to volume, plane and product: each lowers the odds, and none closes the question.
When is emergency care needed?
Seek emergency care now if
- Pain is severe or out of proportion to the injection, or is worsening rather than easing.
- Skin turns white, grey, mottled or dusky, shows a lacy pattern, or feels cold to touch.
- There is any change in vision, a drooping eyelid, or pain and swelling around the eye.
These findings are difficult to interpret cold, in the evening, when they are easy to explain away. The plan for what to do and who to call belongs before treatment, not during an event.
What should a patient ask before treatment?
What a patient can reasonably ask before any of these areas is treated is what the plan is if something goes wrong, and who will answer the telephone at the hour it happens. An injector may decline a particular treatment in one of these areas, choose a different plane or a different product, or suggest an operation instead. Any of those is a reasonable answer, and a patient is entitled to hear the reasoning.
Sources
- NICE — guidance on cosmetic procedures and injectable filler
- MHRA — information on injectable filler regulation and reporting
- British Association of Plastic, Reconstructive and Aesthetic Surgeons — injectable filler complication guidance
Internal links
Frequently asked questions
Which areas of the face carry the highest risk of occlusion?
The glabella, the nose, the forehead, the temple and the tear trough are the areas most often named, because of the arteries that pass through them and the way those arteries connect with the blood supply of the eye. That does not make treatment of these areas wrong. It makes the technique, the product and the preparation more consequential.
Does a cannula remove the risk?
No. A blunt cannula is generally regarded as less likely to enter a vessel than a sharp needle, and it is often preferred in these areas for that reason. It does not remove the risk, because a cannula can still enter a vessel that it meets end-on, and because the anatomy varies between people. Neither instrument makes an occlusion impossible.
Should I avoid filler in these areas altogether?
That is a decision for a consultation rather than a rule, and it depends on what you want changed and what the alternatives are. An injector may decline a particular treatment in one of these areas, choose a different plane or a different product, or suggest an operation instead. Any of those is a reasonable answer, and a patient is entitled to hear the reasoning.
Risks & Limitations
- The site of the injection is not the site of the damage: filler that enters an artery is carried by the blood flow and lodges downstream.
- Only a filler of the enzyme-dissolvable class can be dissolved. Biostimulators, polycaprolactone and calcium-based fillers cannot.
- Dissolving the product removes the cause; it does not repair tissue that has already lost its blood supply.
- The glabella, nose, forehead, temple and tear trough share a blood supply with the eye, which is why they are treated with particular care.
- A change in vision after a facial injection is an emergency in which minutes matter, and recovery cannot be assumed.
- Where skin or vision has been lost, later treatment can improve an area but does not restore what was there before.
When to Seek Care
- Severe pain out of proportion to the injection, or pain that keeps worsening — seek emergency care now.
- Skin turning white, grey, mottled or dusky, a lacy or blotchy pattern, or skin that feels cold — seek emergency care now.
- Any change in vision, a drooping eyelid, or pain and swelling around the eye — seek emergency care now; minutes matter.
- Blistering, peeling or darkening skin over a treated area — seek emergency care now.
- A severe headache, or weakness or numbness on one side of the body — seek emergency care now and call emergency services.
- A reaction that is not settling but is not in this list — contact your treating team the same day.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — injectable filler safety guidance
- U.S. Food and Drug Administration (FDA) — dermal filler safety information
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.